货号:A336488
                
                同义名:
                    
                        
                            
                                FG-4592; ASP1517
                            
                        
                    
                
                
                
                    
                     
                
            
Roxadustat是一种口服HIF-PHI类抗贫血药,通过抑制PHD酶增加内源性促红素生成并改善铁利用,Ⅲ期OLYMPUS试验证实其可有效纠正非透析依赖性CKD贫血。
 
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 产品名称 | HIF ↓ ↑ | HIF1 ↓ ↑ | PHD1 ↓ ↑ | PHD2 ↓ ↑ | PHD3 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KC7F2 | + HIF-1α, IC50: 20 μM | + HIF-1α, IC50: 20 μM | 98% | ||||||||||||||||
| Roxadustat | ✔ | 98+% | |||||||||||||||||
| Lificiguat | ✔ | 99%+ | |||||||||||||||||
| BAY 87-2243 | ✔ | 99%+ | |||||||||||||||||
| PX-478·2HCl | ✔ | 98%+ | |||||||||||||||||
| 2-Methoxyestradiol | ✔ | 98% | |||||||||||||||||
| LW6 | ++ HIF, IC50: 4.4 μM | BCRP | 99%+ | ||||||||||||||||
| Daprodustat | ✔ | 98+% | |||||||||||||||||
| DMOG | ✔ | 98% | |||||||||||||||||
| FG 2216 | ++ PHD2, IC50: 3.9 μM | 99%+ | |||||||||||||||||
| IOX2 | +++ PHD2, IC50: 21 nM | 99% | |||||||||||||||||
| Molidustat | ++ PHD1, IC50: 480 nM | +++ PHD2, IC50: 280 nM | +++ PHD3, IC50: 450 nM | 98+% | |||||||||||||||
| MK-8617 | ++++ PHD1, IC50: 1 nM | ++++ PHD2, IC50: 1 nM | ++++ PHD3, IC50: 14 nM | 99%+ | |||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 | 
 | 
| 描述 | The family of HIF-PH (HIF prolyl hydroxylase) enzymes are the main molecular to regulate HIF activity through hydroxylation at 2 proline residues and cause the degradation of HIF, thus leading to inhibition on accumulation of functional HIF under normoxia. Roxadustat (FG-4592) is the second generation HIF-PH inhibitor. Treatment with FG-4592 on dose of 5 - 50 μM can stabilize HIF-1α and inhibit apoptosis in tert-Butylhydroperoxide-stimulated PC12 cells. Intraperitoneal injection with FG-4592, 50 mg/kg/day, showed neuroprotection against spinal cord injury through stabilization of HIF-1α in SCI (Traumatic spinal cord injury) mice model[1]. FG-4592 (50 μM) can increase HiPO4-induced mineralization through up-regulation of HIF-1α levels in vascular smooth muscle cells[2]. For Roxadustat can induce elevations in endogenous EPO levels and hemoglobin levels, it is now used to treatment of anemia in chronic kidney disease[3]. | 
| 作用机制 | Most HIF-PH inhibitors are 2-oxogluarate derivatives, region of which can compete with HIF[4]. | 
| Concentration | Treated Time | Description | References | |
| Primary human myotubes | 10 μmol/l | 24 hours | To evaluate the effect of Roxadustat on glucose metabolism, results showed that Roxadustat increased glycolytic rate and inhibited mitochondrial respiration | Diabetologia. 2024 Sep;67(9):1943-1954 | 
| Caco-2 cells | 20, 50, 100 μM | 1, 3, 6, 24 hours | To evaluate the regulatory effect of FG-4592 on FPN expression, results showed that FG-4592 significantly upregulated FPN mRNA and protein levels and promoted FPN transcription through HIF2α binding to HREs on the FPN promoter. | Adv Sci (Weinh). 2024 Mar;11(12):e2307022 | 
| UMR-106 cells | 50 μM | 24 hours | To investigate the effect of FG-4592 on iFGF23 levels in osteoblast-like cells. Results showed that FG-4592 promoted iFGF23 cleavage by upregulating Furin enzyme expression. | Cell Commun Signal. 2025 Apr 25;23(1):200 | 
| HK-2 cells | 50 μM | 24 hours | To investigate the inhibitory effect of FG-4592 on tubular epithelial cell fibrogenesis. Results showed that FG-4592 significantly downregulated the mRNA expression of Fn1, Acta2, and Col1a1. | Cell Commun Signal. 2025 Apr 25;23(1):200 | 
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Tmprss6 knockout mice, anemia of chronic kidney disease (CKD) model, anemia of inflammation (AI) model, 5-fluorouracil-induced chemotherapy-related anemia (CRA) model | Oral gavage | 30 mg/kg | Once daily for 4 weeks | To evaluate the therapeutic effect of FG-4592 on various anemia models, results showed that FG-4592 promoted iron absorption and ameliorated anemia symptoms by stabilizing duodenal Hif2α and upregulating Fpn expression, independent of hepatic Hamp expression. | Adv Sci (Weinh). 2024 Mar;11(12):e2307022 | 
| Sprague-Dawley rats | Chronic kidney disease (CKD) model | Oral gavage | 20 mg/kg | Three times a week for 12 weeks | To evaluate the effect of FG-4592 on renal fibrosis in CKD rats. Results showed that FG-4592 significantly improved renal function and attenuated tubulointerstitial fibrosis. | Cell Commun Signal. 2025 Apr 25;23(1):200 | 
| Dose | Mice[5] (p.o.): 15 mg/kg - 60 mg/kg; rat: 2.5 mg/kg - 10 mg/kg | 
| Administration | p.o. | 
| Pharmacokinetics | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 2.84mL 0.57mL 0.28mL | 14.19mL 2.84mL 1.42mL | 28.38mL 5.68mL 2.84mL | |
| CAS号 | 808118-40-3 | 
| 分子式 | C19H16N2O5 | 
| 分子量 | 352.34 | 
| SMILES Code | O=C(O)CNC(C1=C(O)C2=C(C(C)=N1)C=C(OC3=CC=CC=C3)C=C2)=O | 
| MDL No. | MFCD20040519 | 
| 别名 | FG-4592; ASP1517 | 
| 运输 | 蓝冰 | 
| InChI Key | YOZBGTLTNGAVFU-UHFFFAOYSA-N | 
| Pubchem ID | 11256664 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C | 
| 溶解方案 | DMSO: 105 mg/mL(298.01 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1